- Conditions
- Alzheimer Disease
- Interventions
- E2814
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- La Jolla, California • Indianapolis, Indiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 2,499
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, Waldenström Macroglobulinemia
- Interventions
- panobinostat, everolimus, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Bethesda, Maryland • Rochester, Minnesota
- Conditions
- Leptomeningeal Metastasis
- Interventions
- 186RNL
- Drug
- Lead sponsor
- Cerenome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Glioblastoma Multiforme, Glioblastoma - Category
- Interventions
- Bevacizumab, Magnetic Resonance Spectroscopy (MRS), Border Zone Stereotactic Radiosurgery (BZ-SRS)
- Drug · Procedure
- Lead sponsor
- Ajay Niranjan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Glioblastoma Multiforme
- Interventions
- Verubulin, Temozolomide & Radiation Therapy
- Drug
- Lead sponsor
- Myrexis Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Stanford, California • Houston, Texas
- Conditions
- Cancer Patients First-ever Acute Ischemic Stroke
- Interventions
- Enoxaparin, Aspirin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab Deruxtecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Durham, North Carolina
- Conditions
- Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
- Interventions
- Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
- Drug · Biological · Radiation + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Glioma
- Interventions
- Tamoxifen citrate, Bortezomib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- celecoxib, cyclophosphamide, etoposide, thalidomide
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Interventions
- Conventional Surgery, Laboratory Biomarker Analysis, Sorafenib Tosylate, Temsirolimus
- Procedure · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 190
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Hartford, Connecticut + 118 more
- Conditions
- Cancer, Cancer Central Nervous System, Cancer Thoracic, Cancer, Gastrointestinal, Cancer Gynecologic, Cancer, Genito-Urinary, Cancers Lymphatic, Cancer Head and Neck
- Interventions
- Registry - Observational
- Device
- Lead sponsor
- RefleXion Medical
- Industry
- Eligibility
- Not listed
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- Duarte, California • Palo Alto, California • New Haven, Connecticut + 2 more
- Conditions
- Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Male Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Melanoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
- Procedure · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Brain Tumors, Central Nervous System Tumors
- Interventions
- carboplatin, lomustine, procarbazine hydrochloride, thioguanine, vincristine sulfate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 9 Years
- Enrollment
- 428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2012
- U.S. locations
- 179
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 141 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- O6-benzylguanine, temozolomide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Ependymoma, Medulloblastoma, Childhood, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma, Childhood, Glioma
- Interventions
- SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 26 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2042
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Central Nervous System Tumor, Brain Tumor, Spinal Tumor
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Adult Central Nervous System Germ Cell Tumor, Adult Malignant Meningioma, Adult Medulloblastoma, Adult Noninfiltrating Astrocytoma, Adult Oligodendroglioma, Adult Craniopharyngioma, Adult Meningioma, Brain Metastases, Adult Ependymoma, Adult Pineal Parenchymal Tumor, Adult Brain Stem Glioma, Adult Infiltrating Astrocytoma, Mixed Gliomas, Stage IV Peripheral Primitive Neuroectodermal Tumor
- Interventions
- Sterotactic radiosurgery
- Procedure
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
- Interventions
- Emavusertib, Ibrutinib
- Drug
- Lead sponsor
- Curis, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Duarte, California • Santa Monica, California + 19 more
- Conditions
- Brain Tumors, Central Nervous System Tumors
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Memphis, Tennessee • Seattle, Washington
- Conditions
- Brain Cancer
- Interventions
- Virtual Reality System, Word Search Puzzles
- Other
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Spinal Cord Injury, Spinal Cord Involvement, Spina Bifida, Transverse Myelitis, Polio and Post-polio Syndrome, Syringomyelia, Spinal Stenosis, Spinal Neoplasms, Spinal Cord Diseases
- Interventions
- SCI Hard
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 13 Years to 29 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Radiation Necrosis
- Interventions
- Bevacizumab (Avastin®)
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Central Nervous System Cancer
- Interventions
- Qualitative Interviews
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- Not listed
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado